Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2006): Bettoli V+, Acta Derm Venereol 86(3), 258 (with
ribavirin)
(2003): Jensen SL+, J Drugs Dermatol 2(5), 554 (with ribavirin)
Sarcoidosis
(2007): Perez-Gala S+, J Eur Acad Dermatol Venereol 21(3), 393
(with ribavirin)
(2006): Benali S+, Gastroenterol Clin Biol 30(4), 615 (2 cases)
(2006): Bruch-Gerharz D+, Hautarzt 57(4), 317
(2006): Sanchez-Ruano JJ+, Gastroenterol Hepatol 29(3), 150
(with ribavirin)
(2005): Guilabert A+, Br J Dermatol 152(2), 377
(2005): Hurst EA+, Arch Dermatol 141(7), 865 (with ribavirin)
(2005): Ramos-Casals M+, Medicine (Baltimore) 84(2), 69
(2004): Alfageme Michavila I+, Arch Bronconeumol 40(1), 45
(with ribavirin)
(2004): Blank E, Schoch Letter 52(4), 15 (with ribavirin)
Urticaria (~1%)
Vesiculation
(2003): Gallina K+, JDrugsDermatol2(1), 63
Vitiligo
(2006): Tinio P+, Skinmed 5(1), 50 (with ribavirin)
(2006): Tomasiewicz K+, Adv Ther 23(1), 139 (with ribavirin)
Xerosis (11%)
Hair
Hair – alopecia (22%)
(2006): Demirturk N+, Eur J Dermatol 16(5), 579 (rare) (with
ribavirin)
(2004): Bagheri H+, Pharmacotherapy 24(11), 1546 (with
ribavirin)
Hair – alopecia areata
(2006): Demirturk N+, Eur J Dermatol 16(5), 579 (with ribavirin)
Eyes
Eyelashes – hypertrichosis
(2005): Howaizi M, J Gastroenterol Hepatol 20(12), 1945
Ocular toxicity
(2006): Avila MP+, Arq Bras Oftalmol 69(2), 255 (with ribavirin)
Retinopathy
(2006): Andrade RJ+, Antivir Ther 11(4), 491 (15%) (with
ribavirin)
(2006): Avila MP+, Arq Bras Oftalmol 69(2), 255 (with ribavirin)
(2006): Okuse C+, World J Gastroenterol 12(23), 3756 (5 cases)
(with ribavirin)
Vision blurred
(2004): Bagheri H+, Pharmacotherapy 24(11), 1546 (with
ribavirin)
Other
Anaphylactoid reactions/Anaphylaxis (~1%)
Cough (6%)
Death
(2006): Helbling B+, JViralHepat13(11), 762 (2 cases) (with
ribavirin)
Embolia cutis medicamentosa (Nicolau syndrome)
(2005): Sonntag M+, Hautarzt 56(10), 968
Hypersensitivity (~1%)
Injection-site necrosis
(2005): Dalmau J+, JAmAcadDermatol53(1), 62
Injection-site pain (2%)
Injection-site reactions
(2004): Bagheri H+, Pharmacotherapy 24(11), 1546 (with
ribavirin)
Myalgia/Myositis/Myopathy/Myotoxicity (38–42%)
(2001): Perry CM+, Drugs 61(15), 2263
Nephrotoxicity
(2006): Alves Couto C+, Liver Int 26(10), 1294 (with
ribavirin)
Pain (12%)
Vogt–Koyanagi–Harada disease
(2003): Sylvestre DL+, JViralHepat10(6), 467 (with ribavirin)
PEGAPTANIB
Trade name: Macugen (Eyetech) (Pfizer)
Indications: Age-related macular degeneration (AMD),
neovascular
Category: Vascular endothelial growth factor antagonist
Half-life: 10 (±4) days
Clinically important, potentially hazardous interactions
with: none
Reactions
PEGAPTANIB 419
Skin
Angioedema
(2007): Steffensmeier AC+, Am J Ophthalmol 143(3), 512
Dermatitis (1–5%)
Urticaria
(2007): Steffensmeier AC+, Am J Ophthalmol 143(3), 512
Eyes
Blepharitis (6–10%)
Cataract (10–40%)
(2006): Prescrire Int 15(84), 127
(2006): D’Amico DJ+, Ophthalmology 113(6), 992
Conjunctival hemorrhage (10–40%)
Conjunctivitis (6–10%)
Corneal edema (10–40%)
Endophthalmitis (